News: Gastrointestinal Cancer

VUMC researchers have created the world’s first laboratory model of precancerous changes in the lining of the stomach, a scientific tour de force that is helping to unlock the mysteries of gastric cancer development.

Colorectal cancer researchers from Vanderbilt-Ingram Cancer Center (VICC) have been awarded a Specialized Program of Research Excellence grant from the National Cancer Institute (NCI).

Inflammation synergizes with a cell’s intrinsic genetic program to promote the development of pancreatic cancer.

Investigators are exploring the molecular mechanisms behind the association of chronic inflammation and colon cancer.

Researchers have obtained the first high-resolution image of a molecular “machine” used by the insidious stomach bug Helicobacter pylori to inject a cancer-causing protein into the stomach lining.

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).

A recent study demonstrates that loss of the receptor NOD1 augments inflammatory and injury responses to H. pylori – and points towards NOD1 as a prime target for modification for either preventing or treating H. pylori infections.

Cancer Research UK has awarded a 20-million-pound grant (about $26 million U.S.) to a team of international investigators, including Vanderbilt’s James Goldenring, MD, PhD, to study inflammation-related cancers.

Mary Philip, MD, PhD, has been named a 2019 V Scholar and will receive $200,000 from the V Foundation for Cancer Research.